Shares of Bicycle Therapeutics (BCYC) are up over 26% to $25.80 on Monday afternoon after the company disclosed in an abstract Sunday that 45% of bladder cancer patients responded to its experimental treatment in an early-stage study, Lei Lei Wu of Endpoints News reports. Bicycle’s experimental treatment would compete with Padcev, which is made by Astellas (ALPMF), Pfizer (PFE) and Merck (MRK).
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- RBC starts Bicycle Therapeutics at Outperform on ‘novel and unique platform’
- Bicycle Therapeutics initiated with an Outperform at RBC Capital
- Bicycle Therapeutics downgraded to Neutral from Buy at B. Riley
- Bicycle Therapeutics reports Q2 EPS (77c), consensus ($1.10)
- Bicycle Therapeutics Clears Debt Early, Strengthens Finances